infliximab
Selected indexed studies
- Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. (Clin Pharmacokinet, 2018) [PMID:29330783]
- Infliximab biosimilar GP1111: a review of 5 years' post-approval experience. (Expert Opin Biol Ther, 2024) [PMID:38976286]
- Efficacy and safety of infliximab in patients with autoimmune hepatitis. (Hepatology, 2025) [PMID:39250458]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. (2018) pubmed
- Infliximab biosimilar GP1111: a review of 5 years' post-approval experience. (2024) pubmed
- Efficacy and safety of infliximab in patients with autoimmune hepatitis. (2025) pubmed
- SB2: An Infliximab Biosimilar. (2017) pubmed
- PF-06438179/GP1111: An Infliximab Biosimilar. (2018) pubmed
- Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease. (2025) pubmed
- Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC. (2026) pubmed
- Immunogenicity of infliximab and adalimumab. (2019) pubmed
- Can infliximab serve as a new therapy for neuropsychiatric symptoms? (2025) pubmed
- Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. (2019) pubmed